Breaking News

Molecular Profiles Opens Nottingham Site

July 12, 2013

Completes successful MHRA inspection

Molecular Profiles has opened its new facility in Nottingham following a successful MHRA inspection. The £9 million, 30,000-sq.-ft. pharmaceutical production facility will provide clinical manufacturing capabilities designed to handle a range of non-sterile dosage forms such as solids, liquids, semi-solids and inhaled products. The investment adds six GMP suites, new labs, and a dedicated clinical packing area to support Phase I and II clinical trials. The facility also allows for the manufacture of highly potent compounds up to OEB 4 level with manufacturing batch scale of up to 30kg.
 
Nikin Patel, chief executive officer of Molecular Profiles, said, “Receiving our license from the MHRA for our new site is probably the biggest milestone for our business since we set-up shop so is naturally a very exciting time for everyone involved. From a commercial perspective, we are very much open for business and have already received significant interest from companies looking to use our manufacturing capabilities to assist with their clinical trial requirements."
 
The company's new vice president Steve Kemp added, “We have enjoyed a sustained and gradual period of growth over the last decade driven by our consulting, formulation development and analytical services but we are expecting our expanded manufacturing facilities to take us to the next level by helping us better compete on a global scale.”
 

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important